TIGIT

Across TCGA pan-cancer cohorts, TIGIT RNA differs between tumor and matched normal tissue in 7 of 18 cancer types tested, making tumor–normal expression one of TIGIT’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where TIGIT RNA is more highly expressed in tumor relative to normal tissue. In most cancer types TIGIT is over-expressed in tumor.

KIRC, HNSC, and LUAD are the cancer types where TIGIT tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TIGIT RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Male	IV	+1.639	<.001	11	view →
HNSC	All	IV	+0.940	<.001	11	view →
LUAD	Female	All	+0.965	<.001	9	view →
STAD	Female	All	+1.841	<.001	8	view →
BRCA	All	All	+0.963	<.001	6	view →
ESCA	All	All	+0.973	.011	2	view →
LUSC	All	All	+0.366	.048	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 7 strongest of 7 lineages.

TIGIT–KIRC

Open the KIRC breakdown →